CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy

Purpose We investigated implanting computed tomography (CT)-guided 125 I seed to treat locally advanced non-small-cell lung cancer (NSCLC) after chemotherapy failure. Methods From January 2005 to July 2010, we recruited 69 patients with locally advanced NSCLC who had each had first-line chemotherapy...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2014-08, Vol.140 (8), p.1383-1390
Main Authors: Zhang, Tao, Lu, Mingjian, Peng, Sheng, Zhang, Weidong, Yang, Guang, Liu, Zhenyin, Singh, Sristi, Yang, Yadi, Zhang, Fujun, Gao, Fei
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - mortality
Adenocarcinoma - radiotherapy
Aged
Aged, 80 and over
Cancer Research
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - radiotherapy
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - radiotherapy
Disease-Free Survival
Drug Resistance, Neoplasm
Female
Hematology
Humans
Internal Medicine
Iodine Radioisotopes - administration & dosage
Kaplan-Meier Estimate
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - radiotherapy
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Article – Clinical Oncology
Radiopharmaceuticals - administration & dosage
Tomography, X-Ray Computed
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose We investigated implanting computed tomography (CT)-guided 125 I seed to treat locally advanced non-small-cell lung cancer (NSCLC) after chemotherapy failure. Methods From January 2005 to July 2010, we recruited 69 patients with locally advanced NSCLC who had each had first-line chemotherapy four to six times but had progressive disease; 34 received 125 I seed implantation with second-line chemotherapy (Group A) and 35 received second-line chemotherapy only (Group B). Results Mean follow-up was 32 months (range 5–56 months). Overall 2-year local control rate for existing lung lesions was Group A: 39.9 %; Group B: 12.5 % ( P   0.05). Local 3-, 24-month, and median progression-free survival was Group A: 100 and 79.1 % at 11 months; Group B: 76.5 and 18.7 % at 7.3 months, respectively. The groups did not significantly differ in treatment toxicity. Chest pain remission was Group A: 82.1 % (23/28); Group B: 30.8 % (8/26) ( P  
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-014-1655-x